Last edition
News about "central nervous system "
Genethon Partners with AskBio on Pompe Gene Therapy
The licensing deal enables AskBio to advance the clinical development of Genethon’s investigational gene therapy for Pompe disease through an industry partnership.
Central Nervous System | 15/01/2026 | By News Bureau
Cipla to Enter Weight Management Segment, Expands Focus on Oncology and CNS Therapies
Cipla is set to enter India’s growing weight management market as part of its broader strategy to expand across emerging therapeutic segments.
Central Nervous System | 14/07/2025 | By Dineshwori | 206
JCR Pharmaceuticals and Modalis to Develop Novel Gene Therapy
The purpose of this joint agreement is to conduct pre-clinical studies for the development of a new gene therapy for the undisclosed CNS disease by applying J-Brain Cargo®, JCR’s proprietary technology.
Central Nervous System | 06/01/2025 | By Aishwarya | 376
AbbVie Announces Acquisition of Aliada Therapeutics
Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in a Phase 1 clinical trial.
Central Nervous System | 13/12/2024 | By Aishwarya | 387
AbbVie and Gedeon Richter to Develop Novel Targets for Neuropsychiatric Conditions
This collaboration expands upon the success of nearly two decades of partnership on central nervous system (CNS) projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA) and the discovery of investigational drug candidate ABBV-932 for the treatment of bipolar depression and generalized anxiety disorder.
Central Nervous System | 25/10/2024 | By Aishwarya | 215
Lupin Rolls Out First Generic Version of Oracea
Lupin has unveiled the first generic version of Oracea (Doxycycline Capsules, 40 mg), in the United States.
Central Nervous System | 10/04/2024 | By Aishwarya | 589
First Use of Kyverna KYV-101 in Patients with Progressive Multiple Sclerosis Published
Kyverna Therapeutics, Inc. has announced about a recent report published in Med that describes the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in two patients suffering from progressive multiple sclerosis (MS).
Central Nervous System | 30/03/2024 | By Manvi | 1004
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy